title: Low circulating endogenous secretory receptor for AGEs predicts cardiovascular mortality in patients with end-stage renal disease.
abstract: OBJECTIVE
  Receptor for advanced glycation end-products (RAGE) is involved in diabetic vascular complications. We have recently shown that plasma endogenously secretory RAGE (esRAGE), an alternatively spliced form of RAGE, is closely associated with metabolic syndrome and atherosclerosis. Here, we evaluated if plasma esRAGE is a predictor of cardiovascular mortality in a cohort of 206 (171 nondiabetic) patients with end-stage renal diseases (ESRD).
  
  
  RESULTS
  The cohort was followed for a median of 111 months, and 74 deaths including 34 cardiovascular deaths were recorded. Plasma esRAGE was measured at baseline. Cumulative incidence of cardiovascular death by Kaplan-Meier estimation was significantly higher in subjects in the lowest tertile of plasma esRAGE than those in the middle or the highest tertile both in all and nondiabetic subjects alone. In all subjects, as compared with the lowest tertile of plasma esRAGE, the hazards ratios for the highest and middle tertile were 0.40 (95% CI, 0.18 to 0.89) and 0.26 (0.10 to 0.66), respectively. The higher risk for lower esRAGE was still significant even after adjusted either with body mass index, hypertension, dyslipidemia and vascular complications, but was confounded by age and diabetes.
  
  
  CONCLUSIONS
  Low circulating esRAGE is a predictor for cardiovascular mortality in ESRD patients.
authors.affiliation: Department of Metabolism, Endocrinology and Molecular Medicine, Osaka City University Graduate School of Medicine, 1-4-3, Asahi-machi, Abeno-ku, Osaka 545-8585, Japan. hidekoyama@med.osaka-cu.ac.jp
authors.forename: Hidenori
authors.initials: H
authors.lastname: Koyama
authors.forename: Tetsuo
authors.initials: T
authors.lastname: Shoji
authors.forename: Shinya
authors.initials: S
authors.lastname: Fukumoto
authors.forename: Kayo
authors.initials: K
authors.lastname: Shinohara
authors.forename: Takuhito
authors.initials: T
authors.lastname: Shoji
authors.forename: Masanori
authors.initials: M
authors.lastname: Emoto
authors.forename: Katsuhito
authors.initials: K
authors.lastname: Mori
authors.forename: Hideki
authors.initials: H
authors.lastname: Tahara
authors.forename: Eiji
authors.initials: E
authors.lastname: Ishimura
authors.forename: Ryusuke
authors.initials: R
authors.lastname: Kakiya
authors.forename: Tsutomu
authors.initials: T
authors.lastname: Tabata
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Yamamoto
authors.forename: Yoshiki
authors.initials: Y
authors.lastname: Nishizawa
mesh_terms: D000368:Aged; D002318:Cardiovascular Diseases / Q000097:blood* / Q000175:diagnosis / Q000401:mortality*; D015331:Cohort Studies; D003920:Diabetes Mellitus / Q000097:blood / Q000175:diagnosis / Q000401:mortality; D005260:Female; D017127:Glycation End Products, Advanced / Q000097:blood*; D006801:Humans; D007333:Insulin Resistance; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000401:mortality*; D008297:Male; D008875:Middle Aged; D016017:Odds Ratio; D011237:Predictive Value of Tests; D011379:Prognosis; D012307:Risk Factors
chemical_list: D017127:Glycation End Products, Advanced